PAIN
Volume 141, Issue 1 , Pages 60-69 , January 2009

Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin

  • Parisa Gazerani

      Affiliations

    • Center for Sensory-Motor Interactions (SMI), Department of Health Sciences and Technology, Aalborg University, Fredrik Bajers Vej 7 D-3, DK-9220 Aalborg, Denmark
    • Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, Canada
    • ,
  • Natalia Spicina Pedersen

      Affiliations

    • Center for Visceral Biomechanics and Pain, Department of Gastroenterology, Aalborg University Hospital, Denmark
    • ,
  • Camilla Staahl

      Affiliations

    • Center for Sensory-Motor Interactions (SMI), Department of Health Sciences and Technology, Aalborg University, Fredrik Bajers Vej 7 D-3, DK-9220 Aalborg, Denmark
    • Center for Visceral Biomechanics and Pain, Department of Gastroenterology, Aalborg University Hospital, Denmark
    • ,
  • Asbjørn Mohr Drewes

      Affiliations

    • Center for Sensory-Motor Interactions (SMI), Department of Health Sciences and Technology, Aalborg University, Fredrik Bajers Vej 7 D-3, DK-9220 Aalborg, Denmark
    • Center for Visceral Biomechanics and Pain, Department of Gastroenterology, Aalborg University Hospital, Denmark
    • ,
  • Lars Arendt-Nielsen

      Affiliations

    • Center for Sensory-Motor Interactions (SMI), Department of Health Sciences and Technology, Aalborg University, Fredrik Bajers Vej 7 D-3, DK-9220 Aalborg, Denmark
    • Corresponding Author InformationCorresponding author. Tel.: +45 9940 8830; fax: +45 9815 4008.
    web address

Received 4 March 2008 ,Revised 9 October 2008 ,Accepted 14 October 2008.

References 

  1. Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache. 2003;43:S9–S15
  2. Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology. 2005;26:785–793
  3. Apostolidis A, Popat R, Yiangou Y, Cockayne D, Ford AP, Davis JB, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol. 2005;174:977–982
  4. Arezzo JC. Possible mechanisms for the effects of botulinum toxin on pain. Clin J Pain. 2002;18:S125–S132
  5. Argoff CE. A focused review on the use of botulinum toxins for neuropathic pain. Clin J Pain. 2002;18:S177–S181
  6. Ateş Y. Botulinum toxin for the treatment of headaches: a review of current practices and evidence based-data. Agri. 2006;18:5–11
  7. Bach-Rojecky L, Lacković Z. Antinociceptive effect of botulinum toxin type a in rat model of carrageenan and capsaicin induced pain. Croat Med J. 2005;46:201–208
  8. Bach-Rojecky L, Relja M, Lackovic Z. Botulinum toxine type A in experimental neuropathic pain. J Neural Transm. 2005;112:215–219
  9. Bartlett MS. The use of transformations. Biometrics. 1947;3:39–52
  10. Blersch W, Schulte-Mattler WJ, Przywara S, May A, Bigalke H, Wohlfarth K. Botulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized study. J Neurol Sci. 2002;205:59–63
  11. Braune C, Erbguth F, Birklein F. Dose thresholds and duration of the local anhidrotic effect of botulinum toxin injections: measured by sudometry. Br J Dermatol. 2001;144:111–117
  12. Brin MF, Fahn S, Moskowitz C, Friedman A, Shale HM, Greene PE, et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord. 1987;2:237–254
  13. Caterina MJ, Leffler A, Malmberg AB, Martin WJ, Trafton J, Petersen-Zeitz KR, et al. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science. 2000;288:306–313
  14. Caterina MJ. Transient receptor potential ion channels as participants in thermosensation and thermoregulation. Am J Physiol Regul Integr Comp Physiol. 2007;292:R64–76
  15. Cruccu G, Anand P, Attal N, Garcia-Larrea L, Haanpa¨a¨ M, Jørum E, et al. EFNS guidelines on neuropathic pain assessment. Eur J Neurol. 2004;11:153–162
  16. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004;107:125–133
  17. Cui M, Li S, You S, Khanijou S, Aoki KR. Mechanisms of the antinociceptive effect of subcutaneous Botox inhibition of peripheral and central nociceptive processing (abstract). Naunyn Schmiedebergs Arch Pharmacol. 2002;365:R17
  18. Dolly JO, Aoki KR. The structure and mode of action of different botulinum toxins. Eur J Neurol. 2006;13:1–9
  19. Evers S, Vollmer-Haase J, Schwaag S, Rahmann A, Husstedt IW, Frese A. Botulinum toxin A in the prophylactic treatment of migraine–a randomized, double-blind, placebo-controlled study. Cephalalgia. 2004;24:443–838
  20. Fujisawa M, Shoji S, Ishibashi K, Clark GT. Pressure pain threshold with and without iontophoretic anesthesia of the masseter muscle in asymptomatic males. J Orofac Pain. 1999;13:97–103
  21. Gazerani P, Staahl C, Drewes AM, Arendt-Nielsen L. The effects of Botulinum toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain. 2006;122:315–325
  22. Greenspan JD, McGillis SL. Stimulus features relevant to the perception of sharpness and mechanically evoked cutaneous pain. Somatosens Mot Res. 1991;8:137–147
  23. Humeau Y, Doussau F, Grant NJ, Poulain B. How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie. 2000;82:427–446
  24. Ishikawa H, Mitsui Y, Yoshitomi T, Mashimo K, Aoki S, Mukuno K, et al. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J Ophthalmol. 2000;44:106–109
  25. Jankovic J, Schwartz KS. Use of botulinum toxin in the treatment of hand dystonia. J Hand Surg [Am]. 1993;18:883–887
  26. Jensen K, Andersen HO, Olesen J, Lindblom U. Pressure pain threshold in human temporal region. Evaluation of a new pressure algometer. Pain. 1986;25:313–323
  27. Klein AW, Mantell A. Electromyographic guidance in injecting botulinum toxin. Dermatol Surg. 1998;24:1184–1186
  28. Koltzenburg M, Lundberg LE, Torebjork HE. Dynamic and static components of mechanical hyperalgesia in human hairy skin. Pain. 1992;51:207–219
  29. Kosek E, Ekholm J, Hansson P. Pressure pain thresholds in different tissues in one body region. The influence of skin sensitivity in pressure algometry. Scand J Rehabil Med. 1999;31:89–93
  30. Krämer HH, Angerer C, Erbguth F, Schmelz M, Birklein F. Botulinum Toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin. J Neurol. 2003;250:188–193
  31. LaMotte RH, Lundberg LE, Torebjork HE. Pain, hyperalgesia and activity in nociceptive C units in humans after intradermal injection of capsaicin. J Physiol. 1992;448:749–764
  32. LaMotte RH, Shain CN, Simone DA, Tsai EF. Neurogenic hyperalgesia psychophysical studies of underlying mechanisms. J Neurophysiol. 1991;66:190–211
  33. Luvisetto S, Marinelli S, Cobianchi S, Pavone F. Anti-allodynic efficacy of botulinum neurotoxin A in a model of neuropathic pain. Neuroscience. 2007;145:1–4
  34. Mancini F, Zangaglia R, Cristina S, Sommaruga MG, Martignoni E, Nappi GC. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord. 2003;18:685–688
  35. Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache. 2005;45:293–307
  36. McMahon HT, Foran P, Dolly JO, Verhage M, Wiegant VM, Nicholls DG. Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma-aminobutyric acid aspartate and met-enkephalin release from synaptosomes Clues to the locus of action. J Biol Chem. 1992;267:21338–21343
  37. Morenilla-Palao C, Planells-Cases R, García-Sanz N, Ferrer-Montiel A. Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. J Biol Chem. 2004;279:25665–25672
  38. Oguma K, Fujinaga Y, Inoue K. Structure and function of Clostridium botulinum toxins. Microbiol Immunol. 1995;39:161–168
  39. Pacchetti C. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord. 2003;18:685–688
  40. Park HJ, Lee Y, Lee J, Park C, Moon DE. The effects of botulinum toxin A on mechanical and cold allodynia in a rat model of neuropathic pain. Can J Anaesth. 2006;53:470–477
  41. Pearce LB, First ER, MacCallum RD, Gupta A. Pharmacologic characterization of botulinum toxin for basic science and medicine. Toxicon. 1997;35:1373–1412
  42. Purkiss J, Welch M, Doward S, Foster K. Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol. 2000;59:1403–1406
  43. Purkiss JR, Welch MJ, Doward S, Foster KA. Capsaicin stimulates release of substance P from dorsal root ganglion neurons via two distinct mechanisms. Biochem Soc Trans. 1997;25:542S
  44. Reid KI, Carlson C, Rayens MK, Gracely RH. The influence of cutaneous tissue afferents on masticatory pain-pressure thresholds. J Orofac Pain. 1996;10:324–329
  45. Saper JR, Mathew NT, Loder EW, DeGryse R, VanDenburgh AM. A double-blind randomised placebo-controlled exploratory study comparing injection sites with low doses of botulinum toxin type A in the prevention of episodic migraine. J Neurol. 2005;252:II-58
  46. Schnider P, Binder M, Auff E, Kittler H, Berger T, Wolff K. Double-blind trial of botulinum A toxin for the treatment of focal hyperhidrosis of the palms. Br J Dermatol. 1997;136:548–552
  47. Schulte-Mattler WJ, Leinisch E. Evidence based medicine on the use of botulinum toxin for headache disorders. J Neural Transm. 2008;115:647–651
  48. Schulte-Mattler WJ, Opatz O, Blersch W, May A, Bigalke H, Wohlfahrt K. Botulinum toxin A does not alter capsaicin-induced pain perception in human skin. J Neurol Sci. 2007;260:38–42
  49. Serra J, Campero M, Ochoa J. Flare and hyperalgesia after intradermal capsaicin injection in human skin. J Neurophysiol. 1998;80:2801–2810
  50. Silberstein SD, Göbel H, Jensen R, Elkind AH, DeGryse R, Walcott JM, et al. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia. 2006;26:790–800
  51. Silberstein SD, Stark SR, Lucas SM, Christie SN, Degryse RE, Turkel CC. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2005;80:1126–1137
  52. Swartling C, Färnstrand C, Abt G, Stålberg E, Naver H. Side-effects of intradermal injections of botulinum A toxin in the treatment of palmar hyperhidrosis: a neurophysiological study. Eur J Neurol. 2001;8:451–456
  53. Sycha T, Samal D, Chizh B, Lehr S, Gustorff B, Schnider P, et al. A lack of antinociceptive or antiinflammatory effect of botulinum toxin A in an inflammatory human pain model. Anesth Analg. 2006;102:509–516
  54. Takahashi K, Taguchi T, Itoh K, Okada K, Kawakita K, Mizumura K. Influence of surface anesthesia on the pressure pain threshold measured with different-sized probes. Somatosens Mot Res. 2005;22:299–305
  55. Tsui JK, Eisen A, Stoessl AJ, Calne S, Calne DB. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet. 1986;2:245–247
  56. Tugnoli V, Capone JG, Eleopra R, Quatrale R, Sensi M, Gastaldo E, et al. Botulinum toxin type A reduces capsaicin-evoked pain and neurogenic vasodilatation in human skin. Pain. 2007;130:76–83
  57. Voller B, Sycha T, Gustorff B, Schmetterer L, Lehr S, Eichler HG, et al. A randomized, double-blind, placebo-controlled study on analgesic effects of botulinum toxin A. Neurology. 2003;61:940–944
  58. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon. 2000;38:245–258
  59. Yarnitsky D, Sprecher E, Zaslansky R, Hemli JA. Heat pain thresholds: normative data and repeatability. Pain. 1995;60:329–332

PII: S0304-3959(08)00623-4

doi: 10.1016/j.pain.2008.10.005

PAIN
Volume 141, Issue 1 , Pages 60-69 , January 2009

Article Tools

* Image Usage & Resolution